Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Hong Kong · Delayed Price · Currency is HKD 28.38
+0.84 (3.05%)
Apr 17, 2026, 11:59 AM HKT
Shanghai Junshi Biosciences Employees
Shanghai Junshi Biosciences had 2,903 employees as of December 31, 2025. The number of employees increased by 325 or 12.61% compared to the previous year.
Employees
2,903
Change
325
Growth
12.61%
Revenue / Employee
957.72K HKD
Profits / Employee
-335.48K HKD
Market Cap
46.18B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2,903 | 325 | 12.61% | 2,903 | 0 |
| Jun 30, 2025 | 2,670 | - | - | 2,670 | 0 |
| Dec 31, 2024 | 2,578 | - | - | 2,578 | 0 |
| Dec 31, 2022 | 2,961 | 156 | 5.56% | 2,961 | 0 |
| Dec 31, 2021 | 2,805 | 352 | 14.35% | 2,805 | 0 |
| Dec 31, 2020 | 2,453 | 1,067 | 76.98% | 2,453 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| RemeGen | 3,048 |
| Keymed Biosciences | 1,625 |
| Biocytogen Pharmaceuticals (Beijing) | 1,306 |
| InnoCare Pharma | 1,176 |
| Ascentage Pharma Group International | 767 |
Shanghai Junshi Biosciences News
- 4 weeks ago - Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 weeks ago - Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications - GlobeNewsWire
- 7 weeks ago - Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) - PRNewsWire
- 7 weeks ago - Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) - GlobeNewsWire
- 4 months ago - Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis - GlobeNewsWire
- 5 months ago - Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients - GlobeNewsWire
- 7 months ago - Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints - GlobeNewsWire